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Multibranched peptides (SPCs) derived either from the fusion protein (gp41) sequence or from the cleavage sequence
of the human immunodeficiency virus type 1 envelope were chemically synthesized and tested for their ability to inhibit
both syncytium formation and HIV production in CD4/ cells. The gp41-derived SPCs had no effect. In contrast, an SPC
encompassing the envelope cleavage sites strongly inhibited both HIV Env-induced syncytium formation and viral production.
q 1996 Academic Press, Inc.
The human immunodeficiency (HIV) virus type 1 enve- less well known than those of the gp120 subunit, may
be altered by SPCs: (i) gp160 oligomerizes during biosyn-lope precursor gp160 is cleaved into gp41 and gp120.
The transmembrane fusion protein (gp41) is about 350 thesis and at least two gp41 domains (positions 538–
593 and 653–677) appear to be involved in this processamino acids long (1).
Synthetic multibranched peptides (SPCs) derived from (7, 10). Peptides derived from these regions may interfere
with gp160 oligomerization, which is required for its bio-the hypervariable V3 loop of gp120 (e.g., [GPGRAF]8 ,
SPC3) inhibit replication of various virus isolates and synthesis (1); (ii) cellular protease cleaves gp160 at two
sites between positions 505–509 and 513–516 duringimpair syncytium formation in HIV-1- and HIV-2-infected
CD4/ cell cultures (2 – 4). Various linear peptides derived Env intracellular routing to give gp120–gp41 (1). This
cleavage is required for gp41 fusion activity (1). Possiblyfrom HIV and HTLV-1 proteins have similar antiviral activ-
ity (5–9). The mode of action of these compounds re- the machinery involved in this processing, including pro-
teases and chaperones, could be blocked by SPCs corre-mains unclear but they might interfere with postbinding
events required for virus entry into the host cell. sponding to the cleavage sites; (iii) membrane fusion
also requires exposure of the hydrophobic N-terminalUsing a design process and peptide synthesis protocol
similar to our previous studies (2–4), we tried to inhibit fusion domain of gp41 after gp120–CD4 binding, which
results in conformational changes (1). gp41-derivedthe activity of gp41 by using gp41-derived SPCs. The
rationale for testing such Env-derived SPCs was as fol- SPCs could interfere with these events via complexes
formed with some extracellular parts of gp41 as de-lows:
scribed for gp41-derived linear peptides (5, 11); (iv) Env-
(1) SPCs may have an increased affinity for their puta-
derived SPCs may affect gp41/gp120 noncovalent bind-
tive interaction sites due to multivalency (2).
ing at the surface of the virus: an a-helix with a leucine
(2) There is only one short disulfide-bonded loop in
zipper-like motif downstream from the disulfide bonded
gp41 in contrast to the outer membrane glycoprotein
tip appears to be involved in this property and two re-
gp120 which possesses several disulfide-bonded do-
gions of interaction with gp120 have been mapped on
mains (1). Thus, it may be possible for synthetic peptides
gp41 (positions 530–595 and 610–640) (1, 7, 11, 12).
to mimic large parts of gp41.
(3) The functions of the various gp41 regions, although Here we designed and synthesized radially branched
peptides derived from consensus sequences for either
gp41 (eight branches) or the gp41 – gp120 junction (four1 To whom correspondence and reprint requests should be ad-
branches) (Table 1), as described in (2 – 4). SPCs weredressed at URA 1455, Faculte´ de Me´decine Nord, Boulevard Pierre
Dramard, 13916 Marseille Cedex 20 France. Fax: 33-91 69 88 39. designed according to their chemical synthesis feasibil-
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TABLE 1
V3 Loop- and gp41-Derived SPCs
Env region: V3 loop////495 gp120/gp41 junction 515 gp41 sequence 535
Sequence: GPGRAF////KIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGARSMTLTVQARQ
Peptide: SPC3 CLV A B
555 575 595 615
LLSGIVQQQ NNLLRAI EAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKS
C D E F G
635 655 675 850
LEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF // [TMD] //PRRIRQGLERILL
H I J
Note. V3 loop- and gp41-derived SPCs (bold) were synthesized. The regions conserved in different HIV-1 isolates are underlined. [TMD], transmem-
brane domain.
ity, sequence identity between HIV-1, HIV-2, and SIV, described in (13). Cells were then incubated in the pres-
ence of SPCs (1004 to 31 1007 M) in cell culture mediumand the literature of linear peptides with antiviral activ-
ity. We tested the ability of such SPCs to prevent (i) in microtiter well plates as in (3); 15 hr postinfection,
syncytia were scored and cell viability was assessedHIV Env-induced syncytium formation, a marker of both
gp120 – CD4 binding and subsequent gp41 fusion activ- by trypan blue staining. Alternatively, C8166 cells were
infected with HIVHX10 ; 3 days postinfection, both HIV-ity, and (ii) HIV production. In a syncytium formation
assay, CD4/ CEM cells were infected with a recombi- induced syncytium formation and p25 antigen produc-
tion were analyzed as in (14).nant vaccinia virus expressing HIVLai Env for 3 hr as
The short gp41-derived SPCs at noncytotoxic concen-
trations had no inhibitory activity (Table 2). The SPC cor-
TABLE 2
responding to the cleavage sites (SPC CLV) inhibited as
Antiviral Activity of the SPCs efficiently as SPC3 (positive control) (2–4) (i) syncytium
formation induced by either HIV Env-expressing VV or
Toxicity-free
HIV (Table 2) and (ii) production of both HIV-1 (Table 2)concentration Syncytium
and HIV-2 (data not shown; this was obtained usingof the SPC formation HIV infection
SPC (M) [IC90 (M)] [IC90 (M)] Daudi cells infected with LAV-2/B (15)). Since SPC CLV
had antiviral properties similar to those of SPC3 (a pep-
Negative control tide under phase II clinical trials) (2–4) in our assays,
(eight GPGKTL
SPC CLV is a promising anti-HIV candidate.motifs) 1004 None None
The inactivity of the gp41-derived short SPCs contrastsPositive control: SPC3
(eight GPGRAF with the antiviral properties of other long gp41-derived
motifs) 3 1 1005 1005 1006 peptides. For example, two linear peptides derived from
CLV 3 1 1005 1005 1006 region 640–680 and one peptide from the leucine zipper-
A 1004 None None
like motif (sequence 555–595) strongly inhibit HIV infec-B 1004 None None
tion of CD4/ cells (5, 11). In addition, a monoclonal anti-C 3 1 1005 None None
D 3 1 1006 None None body against the highly conserved sequence 667–672
E 1004 None None neutralizes HIV infectivity (16), a gp41-derived peptide
F 1005 None None (sequence 579–611) binds to gp120 (7 ), and a peptide
G 3 1 1005 None None
derived from sequence 637–666 interacts with the gp41H 1004 None None
fusion domain to impair HIV infectivity (17). Surprisingly,I 1004 None None
J 3 1 1005 None None SPCs derived from these regions did not affect syncytium
formation and viral production in our assays. Possibly
Note. To assay inhibition of syncytium formation, CD4/ CEM cells SPCs with longer branches would be active. This is under
were infected with HIV Env-expressing VV and incubated in microtitra-
investigation.tion plates with the SPCs (1004 to 3 1 1007 M) for 15 hr; syncytia were
counted. To test inhibition of HIV production, C8166 cells were infected
with HIV and then cultured in the presence of the SPCs for 3 days; ACKNOWLEDGMENTS
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